AU2018375695B2 - Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins - Google Patents

Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins Download PDF

Info

Publication number
AU2018375695B2
AU2018375695B2 AU2018375695A AU2018375695A AU2018375695B2 AU 2018375695 B2 AU2018375695 B2 AU 2018375695B2 AU 2018375695 A AU2018375695 A AU 2018375695A AU 2018375695 A AU2018375695 A AU 2018375695A AU 2018375695 B2 AU2018375695 B2 AU 2018375695B2
Authority
AU
Australia
Prior art keywords
seq
gii
acid sequence
amino acid
norovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018375695A
Other languages
English (en)
Other versions
AU2018375695A1 (en
Inventor
Marc-Andre D'aoust
Pierre-Olivier Lavoie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aramis Biotechnologies Inc
Original Assignee
Aramis Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aramis Biotechnologies Inc filed Critical Aramis Biotechnologies Inc
Publication of AU2018375695A1 publication Critical patent/AU2018375695A1/en
Assigned to ARAMIS BIOTECHNOLOGIES INC. reassignment ARAMIS BIOTECHNOLOGIES INC. Request for Assignment Assignors: MEDICAGO INC.
Application granted granted Critical
Publication of AU2018375695B2 publication Critical patent/AU2018375695B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AU2018375695A 2017-11-30 2018-11-30 Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins Active AU2018375695B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593006P 2017-11-30 2017-11-30
US62/593,006 2017-11-30
US201862712744P 2018-07-31 2018-07-31
US62/712,744 2018-07-31
PCT/CA2018/051530 WO2019104439A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Publications (2)

Publication Number Publication Date
AU2018375695A1 AU2018375695A1 (en) 2020-06-11
AU2018375695B2 true AU2018375695B2 (en) 2025-01-02

Family

ID=66663733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018375695A Active AU2018375695B2 (en) 2017-11-30 2018-11-30 Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins

Country Status (15)

Country Link
US (2) US11602558B2 (https=)
EP (1) EP3717648A4 (https=)
JP (2) JP7579143B2 (https=)
KR (1) KR102878449B1 (https=)
CN (1) CN111727255A (https=)
AU (1) AU2018375695B2 (https=)
BR (1) BR112020010799A2 (https=)
CA (1) CA3083857A1 (https=)
IL (1) IL274736A (https=)
MX (1) MX2020005530A (https=)
PH (1) PH12020550732A1 (https=)
RU (1) RU2020116307A (https=)
SG (1) SG11202004668WA (https=)
WO (1) WO2019104439A1 (https=)
ZA (2) ZA202003831B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420339B2 (ja) * 2019-10-11 2024-01-23 学校法人北里研究所 変異ノロウイルス粒子とその生産方法
WO2022081870A1 (en) * 2020-10-14 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized norovirus virus-like particles as vaccine immunogens
CN113481328B (zh) * 2021-07-23 2023-10-27 中国科学院微生物研究所 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物
EP4422681A4 (en) * 2021-10-27 2025-11-19 Univ Pennsylvania VACCINE AGAINST A NOROVIRUS AND METHODS OF USE
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用
CN118773218B (zh) * 2024-08-22 2025-09-30 中国医学科学院医学生物学研究所 一种诺如病毒gii.17型病毒样颗粒及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191264A1 (en) * 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
WO2018170603A1 (en) * 2017-03-23 2018-09-27 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PH12012500565B1 (en) * 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
EP2956169B1 (en) * 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP3583950A1 (en) * 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
JP5963811B2 (ja) 2014-07-18 2016-08-03 オリンパス株式会社 治療用超音波振動子
EP3037386A1 (en) 2014-12-23 2016-06-29 Casale SA A plant and a process for ammonia production with cryogenic purification, and a related method of revamping
WO2016200951A1 (en) * 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191264A1 (en) * 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
WO2018170603A1 (en) * 2017-03-23 2018-09-27 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein 4 February 2017 (2017-02-04), MA, C. ET AL.: "capsid protein, partial [Norovirus sp.]", XP055616759, retrieved from NCBI Database accession no. APY24054 *

Also Published As

Publication number Publication date
BR112020010799A2 (pt) 2020-11-10
PH12020550732A1 (en) 2021-04-19
SG11202004668WA (en) 2020-06-29
EP3717648A4 (en) 2021-12-01
WO2019104439A1 (en) 2019-06-06
KR102878449B1 (ko) 2025-10-30
AU2018375695A1 (en) 2020-06-11
KR20200092363A (ko) 2020-08-03
US20200330583A1 (en) 2020-10-22
EP3717648A1 (en) 2020-10-07
ZA202003831B (en) 2023-10-25
JP2024109835A (ja) 2024-08-14
US12076388B2 (en) 2024-09-03
CN111727255A (zh) 2020-09-29
US11602558B2 (en) 2023-03-14
IL274736A (en) 2020-07-30
JP2021503962A (ja) 2021-02-15
CA3083857A1 (en) 2019-06-06
US20230293663A1 (en) 2023-09-21
RU2020116307A (ru) 2021-12-30
JP7579143B2 (ja) 2024-11-07
MX2020005530A (es) 2021-01-15
ZA202306500B (en) 2024-10-30

Similar Documents

Publication Publication Date Title
AU2018375695B2 (en) Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins
US11987601B2 (en) Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
KR101963792B1 (ko) 식물에서 광견병 바이러스 유사 입자 생성
EA034733B1 (ru) Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
AU2019295496B2 (en) Influenza virus hemagglutinin mutants
KR20230079057A (ko) 변형된 코로나바이러스 구조 단백질
US11759512B2 (en) Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins
TW202018084A (zh) 修飾之諾羅病毒vp1蛋白及包含修飾之諾羅病毒vp1蛋白之vlp
KR102953120B1 (ko) 인플루엔자 바이러스 헤마글루티닌 돌연변이들
RU2809237C2 (ru) Мутанты гемагглютинина вируса гриппа
WO2023049983A1 (en) Cpmv vlps displaying sars-cov-2 epitopes
CN119947996A (zh) 修饰的乙型流感病毒血球凝集素
CN116457008A (zh) 经修饰的冠状病毒结构蛋白

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ARAMIS BIOTECHNOLOGIES INC.

Free format text: FORMER APPLICANT(S): MEDICAGO INC.

FGA Letters patent sealed or granted (standard patent)